Last Updated: May 19, 2022

   
     


 
Featured Articles

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

HIV.gov | January 20, 2022

Updates in the Pipeline of HIV Therapy

Infectious Disease Special Edition | January 14, 2022

NIH celebrates FDA approval of long-acting injectable drug for HIV prevention

NIH | December 21, 2021

FDA Approves APRETUDE (cabotegravir) for HIV-1 Pre-Exposure Prophylaxis

FDA | December 20, 2021

TAG’s 2021 Pipeline Report: The Latest in HIV and HCV R&D

Treatment Action Group | October 2021

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

AIDSinfo | August 16, 2021

At Last, Generic HIV Prevention Drugs Promise Savings And Access—But Also Reveal Precarious Financing

Health Affairs | May 20, 2021

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

aidsinfo | February 10, 2021

Novel Antiretroviral Agents

Current HIV/AIDS Reports Feb 2020

IAS Panel Releases Updated 2020 Guidelines on ART and HIV Prevention 

Infectious Disease Advisor | December 4, 2020

Changes in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website

Department of Pharmacology & Therapeutics, University of Liverpool

Proportion of serious drug interactions dropping on Liverpool antiretroviral website

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

HIV/AIDS Update- Prezista (darunavir) labeling changes
   
News Updates

NHS England is considering off-label use of Descovy PrEP

Aidsmap | May 17, 2022

FDA Lifts Clinical Hold on Long-Acting Lenacapavir

POZ | May 17, 2022

FDA approves label update to ViiV's long-acting HIV treatment

Outsourcing Pharma | April 26, 2022

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

The Lancet | April 20, 2022

Risk for Incident Liver Damage in Patients With HIV on Antiretroviral Therapy 

Infectious Disease Advisor | April 12, 2022

Counterfeit HIV Drugs: Justice Department Opens Investigation

Medscape | April 11, 2022

Provider Survey: Prior Authorizations Harm Patients

CANN | April 4, 2022

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

The Lancet | April 1, 2022

FDA Approves Triumeq, ViiV Healthcare's Daily Treatment for Children Living With HIV 

Contagion Live | March 30, 2022

ViiV Healthcare announces US FDA approval of Cabenuva for virologically suppressed adolescents living with HIV who are 12 years of age or older and weigh at least 35 kg

MarketScreener | March 30, 2022

Uncertain Future for 2 Long-Acting HIV Therapies

Infectious Disease Special Edition | March 30, 2022

FDA makes oral lead-in optional for long-acting injectable HIV regimen

Healio | March 24, 2022

Bottlenecks are slowing switch to GSK's long-acting HIV injectable Cabenuva: clinician

Fierce Pharma | March 8, 2022

FDA rejects Gilead's HIV drug lenacapavir over glass vial concerns

Healio | March 2, 2022

Evaluation of Sociodemographic Factors and Prevalence of Oral Lesions in People Living with HIV from Cacoal, Rondônia, Amazon Region of Brazil

Int J Environ Res Public Health. 2022 Feb 24;19(5):2614. doi: 10.3390/ijerph19052614.

Long-acting HIV-1 Capsid Inhibitor Sustained Efficacy in Phase 2/3 Study

Precision Vaccinations | February 19, 2022

Cabenuva Approved for 2 Month Injections; Insurers Remain a Barrier to Access

Co-infection Watch | February 2022

HIV: Dual Therapy With Twice-Yearly Injections on the Horizon

Medscape | February 18, 2022

Antiviral Efficacy, Safety, Tolerability of a Novel HIV-1 Maturation Inhibitor (GSK'254) 

Infectious Disease Advisor | January 27, 2022

Multidrug-Resistant HIV With Limited Treatment Options: No Longer an Unmet Need?

Clinical Care Options

Antimicrobial resistance causes more deaths than HIV and malaria

News Medical | January 22, 2022

HIV Provider Organization to Launch New Web Resource on Long-Acting Agents

American Academy of HIV Medicine | January 6, 2022

Dolutegravir-Based Treatment More Effective in Children Living With HIV

Contagion Live | January 6, 2022

Outcomes of Dolutegravir Treatment in Patients With HIV Infection Who Failed Antiretroviral Therapy 

Infectious Disease Advisor | January 5, 2022

HIV Drug Resistance Report - November 2021

ReliefWeb | November 24, 2021

Injectable HIV treatment for patients in UK | HIV AIDS | Health News 

YouTube | November 22, 2021

Clinics will need new systems to administer injectable HIV therapies, says Canadian early adopter 

Aidsmap | November 5, 2021

Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma

NIH | November 4, 2021

Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults

NATAP | October 26, 2021

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression: pOLAR month 12 results 

AIDS. 2021 Oct 13. doi: 10.1097/QAD.0000000000003085.

ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals

ViiV | 28 September 2021

The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis

Antivir Ther. 2020;25(1):21-32. doi: 10.3851/IMP3346

FDA Approves Pfizer Booster Shots for Seniors, High-Risk Americans

docwirenews | September 23, 2021

Agents Used in Antiretroviral Therapy

Clinical Care Options | September 2021

Researchers advance the use of nanoparticles to deliver HIV/AIDS drugs to the brain

FIU News | September 17, 2021

First-in-Class NRTTI Demonstrates Potential as Long-Acting Oral PrEP Against HIV

Contagionlive.com | September 10, 2021

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

Open Forum Infect Dis. 2021 Aug 25;8(9):ofab439. doi: 10.1093/ofid/ofab439. eCollection 2021 Sep.

Direct oral anticoagulants versus warfarin in people living with human immunodeficiency virus 

Int J STD AIDS. 2021 Jul 23;9564624211031728. doi: 10.1177/09564624211031728

Changes to the Epclusa product label for use in pediatrics

FDA | June 2021

Changes to the Mavyret product labeling for use in pediatrics

FDA | June 2021

How modern medication has extended the life span of people with HIV over the past 40 years 

California News Times | May 2021

Six drugmakers are in violation of 340B statute, says HRSA 

Healthcare Finance News | May 18, 2021

Clinical Insights into New Treatment Options for HIV: Cabenuva and Vocabria 

Pharmacy Times | May 10, 2021

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV

Business Wire | May 4, 2021

   

 
         
  2019 Archives 2020 Archives 2021 Archives